Dáil Éireann Debate, Wednesday - 21 April 2021
1845. Deputy Alan Dillon asked the Minister for Health the Covid-19 vaccine drug product manufacturing and supply strategy to combat variants of the Covid-19 virus; the way in which vaccine booster supplies will be procured; if it is planned to use third party or generic manufacturers based here to ensure guaranteed vaccine supply; and if he will make a statement on the matter. [19120/21]
View answerIreland is participating in an EU led procurement process, where the Commission has negotiated a range of contractual agreements with various vaccine suppliers and across a range of technologies on behalf of Member States. Ireland has, through its participation in this process, gained access to a broad range of vaccines that it might not otherwise have access to, and at the cost agreed collectively by the EU.
Recently, the Commission has engaged in negotiations with Pfizer / BioNTech with a view to securing a Purchase Agreement for 900m doses of its vaccine on behalf of Member States, with provision for an additional 900m doses, for 2022/2023. Pfizer / BioNTech's vaccine is based upon mRNA technology, providing scope for it to be adjusted to deal with variants of Covid-19. The vaccine could also be used to provide booster shots, where required. The appropriate mix of vaccine technologies to provide boosters and variants is also being considered by the Steering Board, comprised of the Commission and EU Member States, for the EC procurement process.
In conjunction with this, the new European bio-defence preparedness plan against COVID-19 variants called “HERA Incubator” will work with researchers, biotech companies, manufacturers and public authorities in the EU and globally to detect new variants, provide incentives to develop new and adapted vaccines, speed up the approval process for these vaccines, and ensure scaling up of manufacturing capacities.
